AbbVie's immunology engine has successfully absorbed Humira erosion, but trading at 19.6 times 2026 earnings leaves little cushion. Elevated debt following the $10.9 billion Apogee acquisition and near-term dilution justify a Hold at a $279 target.
Key points
- $32.3 billion in combined 2026 Skyrizi and Rinvoq sales successfully absorbs Humira biosimilar erosion but now constitutes 48% of total revenue.
- 19.6 times 2026 adjusted earnings fully reflects pipeline execution, leaving limited room for multiple expansion given post-acquisition debt.
- $0.46 per share of anticipated Apogee dilution in 2027 tempers near-term earnings per share growth to 8.9% despite healthy double-digit volume gains.
The call
The stock price requires AbbVie to sustain low-double-digit revenue growth while expanding operating margins past 49% through 2027. At $271.36, the shares trade at 19.6 times 2026 guided adjusted earnings and 18.0 times 2027 estimates. The market assumes uninterrupted immunology demand and seamless deleveraging following the $10.9 billion Apogee acquisition.
Revenue mix by product pillar ($ billions)- Skyrizi and Rinvoq
- Humira
- All other products
AbbVie annual revenue mix, 2023-2027E ($B). Source: SEC filings and desk estimates.
We view valuation as balanced. Skyrizi and Rinvoq remain exceptional commercial assets, offsetting Humira decay and expanding across inflammatory bowel disease. However, the $10 billion debt issuance for Apogee, pending Inflation Reduction Act price negotiation on Imbruvica and Vraylar, and ongoing milestone cash commitments cap multiple re-rating near 18.5 times.
Valuation
| Valuation metric | 2026E | 2027E | Method / Source |
|---|
| Worldwide net revenue | $67.6B | $72.5B | Company guidance and desk forecast |
| Operating margin (adjusted) | 46.8% | 49.0% | Operating leverage on immunology |
| Net interest expense | $2.9B | $3.4B | Post-Apogee debt structure |
| Adjusted diluted EPS | $13.86 | $15.10 | Guidance midpoint / desk model |
| Target multiple | , | 18.5× | Long-term biopharma peer average |
| 12-month price target | , | $279.00 | 18.5× 2027E adjusted EPS |
AbbVie warrants an 18.5 times multiple on 2027 earnings, recognizing premium cash generation alongside an elevated $80.8 billion debt burden. With 2.8% capital appreciation plus a 2.5% dividend yield, risk and reward appear evenly matched, supporting a Hold rating.
Share price implied by 2027E valuation multiples- Target ($15.10 EPS)
- Bull ($15.50 EPS)
12-month share price sensitivity to 2027E adjusted EPS and P/E multiple ($). Source: Desk model.
Risks
- Accelerated price concessions in immunology if next-generation oral treatments or biosimilar competition compress net realized prices.
- Regulatory or pipeline delays in Apogee's zumilokibart programs, jeopardizing expected clinical accretion beginning in 2032.
- Expanding government price negotiation under the Inflation Reduction Act eroding cash flow from mature oncology and neuroscience franchises.
What would change my mind
Accelerating aesthetic and oncology demand lifting 2027 adjusted earnings above $16.00 would prompt an upgrade.